Patents by Inventor Stephan Mletzko
Stephan Mletzko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9592245Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: GrantFiled: December 8, 2014Date of Patent: March 14, 2017Assignee: Bayer Intellectual Property GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20150335658Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: July 29, 2015Publication date: November 26, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jochen SCHUMACHER, Manfred SUESSE, Michael DITTGEN, Stephan MLETZKO, Jan-Peter INGWERSEN, Thomas LANGGUTH, Dirk SCHENK, Hubert KAFFL
-
Patent number: 9095691Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: March 15, 2013Date of Patent: August 4, 2015Assignee: Bayer Intellectual Property GmbHInventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20150094287Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Stephan MLETZKO, Rolf SCHÜRMANN, Kerstin GUDE
-
Patent number: 8906890Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: GrantFiled: April 15, 2011Date of Patent: December 9, 2014Assignee: Bayer Intellectual Property GmbHInventors: Stephan Mletzko, Rolf Schurmann, Kerstin Gude
-
Patent number: 8486443Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: GrantFiled: February 4, 2004Date of Patent: July 16, 2013Assignee: Bayer IP GmbHInventors: Jochen Schuhmacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl
-
Publication number: 20130140210Abstract: The present invention relates to a low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.5 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the low E2 and DRSP doses it has surprisingly been found that a very high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: June 6, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20130137664Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: May 30, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20110275601Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 15, 2011Publication date: November 10, 2011Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Stephan MLETZKO, Rolf SCHURMANN, Kerstin GUDE
-
Publication number: 20060251707Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: February 4, 2004Publication date: November 9, 2006Inventors: Jochen Schumacher, Manfred Suesse, Michael Dittgen, Stephan Mletzko, Jan-Peter Ingwersen, Thomas Langguth, Dirk Schenk, Hubert Kaffl